How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,541 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

7481. A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

Status : Unknown Verified January 1996 by NIH AIDS Clinical Trials Information Service. Recruitment status was: Active, not recruiting First Posted : August 31, 2001 Last Update Posted : June 24, 2005 Sponsor: Sequus Pharmaceuticals Information provided by: NIH AIDS Clinical Trials Information Service Study Details Study Description Go to Brief Summary: To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of severe AIDS-related Kaposi's sarcoma (KS (...) combination. Infusions are given on day 1 and every 2 weeks for a total of six cycles. Kaposi's sarcoma lesions are evaluated prior to every cycle, at the end of the last treatment cycle, and 4 weeks following the end of the last treatment. Patients must agree to have one or more representative KS lesions biopsied. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 225 participants Intervention Model: Parallel Assignment Primary Purpose

1999 Clinical Trials

7482. Bexarotene in Treating Patients With Metastatic Breast Cancer

With Metastatic Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00003752 Recruitment Status : Completed First Posted : May 25, 2004 Last Update Posted : May 30, 2013 Sponsor: Ligand Pharmaceuticals Information provided by: National Cancer Institute (NCI) Study Details Study Description Go (...) hormone replacement therapy or low dose corticosteroids for noncancer indication Radiotherapy: See Disease Characteristics Prior radiotherapy allowed Concurrent radiotherapy allowed only to non-indicator tumor(s) that do not represent new disease or disease progression Surgery: Prior surgery allowed Other: At least one month since prior investigational therapy (except hormonal) No other concurrent investigational therapy Concurrent medication with drugs that significantly alter hepatic metabolism (e.g

1999 Clinical Trials

7483. Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis

the sponsorship of Alexion Pharmaceuticals, Inc. In dermatomytosis, humorally-mediated damage to muscle and skin microvasculature appears very important. The deposition of the membrane attack complex (C5-9) on the capillaries has been shown to precede the destruction of muscle fibers and to be a specific finding in the skin lesion. These observations, along with the recent discovery of the effectiveness of intravenous gammaglobulin (IVIG) in dermatomyositis, support the role of complement activation (...) in the pathogenesis of dermatomyositis. Among the activated components of the complement system, the products that are generated after cleavage of C5, namely, C5a and C5b-9, are potent inflammatory mediators with pleiotropic activities. Inhibition of complement activation at C5 would prevent the formation of these pro-inflammatory molecules while allowing the generation of C3b, which is critical for opsonization and immune complex clearance. C5 inhibition therefore represents a potentially effective therapeutic

2000 Clinical Trials

7484. Efficacy Study of Zenapax in Combination With CellCept, Cyclosporine and Corticosteroids in Heart Transplant

at 3 months and 6 months was reported. Median Change From Baseline for LDL/HDL Ratio [ Time Frame: From Baseline (Day -2) to 3 months, and 6 months ] Number of Participants With Marked Laboratory Abnormalities: Hematology Parameters [ Time Frame: Up to 12 months ] A marked reference range was predefined by Roche. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline (...) is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline were considered marked laboratory abnormalities (i.e. potentially clinically relevant). Biochemistry included blood urea nitrogen, creatinine, serum glutamic oxalacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl transferase (GGT), phosphorous, total bilirubin, direct bilirubin, total protein, albumin, glucose

2002 Clinical Trials

7485. DIVA Study

) technique. Samples for serum CTX measurements were collected from participants immediately prior to their IV dosing. Thus, the values reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The change in serum CTX was defined as the relative difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline, using the following formula: Relative change = 100 x (CTX at Month 6/Month 12/Month 24- CTX (...) reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The absolute change from Baseline in serum CTX was defined as the difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline. Only participants with data available at particular timepoint were analyzed. Percentage of Participants With Mean Lumbar Spine (L2 - L4) BMD Above or Equal to Baseline at Month 12 and 24 [ Time Frame: At Month 12

2002 Clinical Trials

7486. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. (PubMed)

opinions of participants on these issues, to complement the explicit opinions expressed in the OMERACT questionnaire. This took place at a conference of rheumatologists, methodologists, biostatisticians, regulatory, pharmaceutical and biotechnology industry personnel with an interest in therapies for patients with RA. Data from patients with RA and randomized clinical trials of second line drugs in patients with RA formed the basis to create 64 patient profiles and 64 trial profiles. The profiles (...) participants scored whether the profile represented important improvement. In the trial profile session, participants did likewise for important difference between the drugs. After structured discussion the group then voted: consensus was defined as agreement by at least 70% of the group. We decided that an important improvement or difference was present in the profiles on which at least 6 of the 8 groups had achieved consensus. The changes in the profiles showing important improvement or difference can

1993 The Journal of rheumatology

7487. Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice. (PubMed)

Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice. To evaluate the effectiveness of a health authority/pharmaceutical company collaborative intervention to influence the choice of proton pump inhibitorsRandomized controlled trial, with general practices forming the unit of allocation and analysis.Constructive working relationships were achieved with five of six pharmaceutical companies involved. One (...) hundred and two out of 140 practitioners in intervention group practices received at least one visit from an industry representative. There were no reports of representatives operating outside their agreed remit. Prescribing in both the intervention and control group moved towards that recommended by the guidelines but there was no difference between the groups in either the proportion of prescriptions in line with the guidelines or the overall cost.Health authorities can achieve professional working

Full Text available with Trip Pro

2000 British journal of clinical pharmacology

7488. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. (PubMed)

controlled trials involving patients scoring > or =15 on the Hamilton Rating Scale for Depression (HAM-D) or > or =18 on the Montgomery-Asberg Depression Rating Scale (MADRS). Searches of the MEDLINE, EMBASE, and International Pharmaceutical Abstracts databases were performed, as were searches of references from retrieved articles and reviews. Drugs included in the comparison were extended-release venlafaxine (venlafaxine-XR); the SSRIs citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline (...) ; and the TCAs amitriptyline, imipramine, desipramine, and nortriptyline. Therapeutic success was defined as a 50% decrease in the HAM-D or MADRS score. Data were extracted by 2 independent evaluators, with differences resolved through consensus discussions. Weighted mean success rates were calculated for each drug class, using a random-effects model. The resulting data represent 44 trials with 63 study arms and 4033 patients with depression. Venlafaxine-XR demonstrated a 73.7% success rate, which

1999 Clinical therapeutics

7489. [Alpress osmotic tablets: a major advance in the management of hypertensive patients]. (PubMed)

, are of clinical importance: whereas efficacy is comparable to that of standard prazosin, the incidence of orthostatic hypotension and of other common adverse reactions to alpha-blockers is decreased by 50%. In conclusion, the pharmacokinetic characteristics of the novel pharmaceutical Alpress represent and advance in the treatment of hypertension. (...) [Alpress osmotic tablets: a major advance in the management of hypertensive patients]. Improvement in patient compliance in hypertension requires perfect acceptability of the treatment. In this respect, the novel pharmaceutical Alpress (osmotic tablet) avoids massive release of prazosin and ensures that an effective plasma concentration is maintained throughout the 24-hour period. The Alpress osmotic tablet is a third-generation osmotic pump which allows the use of a relatively insoluble

1989 Annales de cardiologie et d'angéiologie

7490. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. (PubMed)

results were especially surprising in that the CAST population represented patients in whom the risk of arrhythmic death was only moderate and the risk of proarrhythmia was thought to be low. In contrast, the arrhythmic death rate of the CAST placebo group was unusually low, to the extent that it paralleled the arrhythmic death rate in previous clinical trials of patients surviving myocardial infarction with no ventricular arrhythmia. The excessive arrhythmic death rate in patients taking encainide (...) and flecainide occurred over the duration of the CAST, implying a proarrhythmic effect that may be due to mechanisms that are unique in this population, and thus challenging traditional concepts of proarrhythmia. The existing knowledge regarding the proarrhythmic and negative inotropic effects of encainide and flecainide are reviewed. The previous pharmaceutical database experience with these 2 antiarrhythmic drugs exceeded 3,000 patients; however, there was no indication of this serious proarrhythmic effect

1990 The American journal of cardiology

7491. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. (PubMed)

by Hoechst-Roussel Pharmaceuticals Inc. A total of 449 patients older than 40 years with probable Alzheimer's disease of mild to moderate severity (criteria of the National Institute for Neurological and Communicative Disorders and Stroke--Alzheimer's Disease and Related Disorders Association) entered the study, and 284 completed both baseline and week 24 data collection. A total of 160 caregivers completed time allocation surveys at baseline and at 24 weeks. Patients with Alzheimer's disease received (...) therapy significantly improved cognitive function relative to placebo, and this was associated with decreased unpaid caregiving time at trend levels. Specifically, caregivers of patients in the high-dose velnacrine group (225 mg/day) experienced a partial release from their time involvements, especially in the area of patient supervision, by an average of 3.3 hours per day.To our knowledge, this study represents the first time that the ADAS has been linked to a caregiver outcome. Results suggest

1995 Clinical pharmacology and therapeutics

7492. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. (PubMed)

been tested in patients with partial epilepsy. This work provides an estimate of each drug's efficacy and tolerability compared with placebo. These estimates are compared across drugs to give broad estimates of comparative efficacy and tolerability.Trial reports were found by searching Medline, by searching through journals by hand, and by contacting the pharmaceutical industry. The outcomes chosen were the proportion of patients who (a) have a > or = 50% reduction in seizure frequency (50 (...) % responders); (b) withdrew from the study (any reason); or (c) reported the following side effects: ataxia, dizziness, fatigue, nausea, or somnolence. Overall odds ratio (OR) with 95% confidence intervals (CIs; 50% responders) or 99% CIs; side effects) were calculated.Twenty-nine trials were included, representing 4,091 randomized patients. The ORs for 50% response (95% CI) were GBP, 2.29 (1.53-3.43); LTG, 2.32 (1.47-3.68); TGB, 3.03 (2.01-4.58); TPM, 4.07 (2.87-5.78); VGB, 3.67 (2.44-5.51); and ZNS, 2.7

1997 Epilepsia

7493. A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center. (PubMed)

% in zinc oxide paste on days 1 and 2; anthralin 0.2% with salicylic acid 3% in zinc oxide paste on days 3-5; anthralin 1% with salicylic acid 3% in hydrophilic petrolatum for 60 min on days 8-10 to thicker lesions; and anthralin 2% with salicylic acid 3% in hydrophilic petrolatum for 60 min on day 11 to thicker lesions. On the contralateral side, calcipotriol ointment 0.05 microgram/mL (Leo Pharmaceuticals, Ajax, Ontario) was applied to lesions twice daily. No anthralin or calcipotriol was applied (...) , scalp, or genital regions. For clinical evaluation, the standard Psoriasis Activity and Severity Index (PASI) score was modified by splitting the score for area under 10%; the modified score (mPASI) for an area of coverage of 1%-4% was 0.5 and for an area of 5%-9% was 1. The head and neck area was excluded from the analysis since neither anthralin nor calcipotriol was used at these sites. Each half-body was considered to represent 100% in the area score determination. The maximum modified score

1998 International journal of dermatology

7494. Evidence of clinical efficacy of homeopathy. A meta-analysis of clinical trials. HMRAG. Homeopathic Medicines Research Advisory Group. (PubMed)

, Biosis, PsychInfo, Cinahl, British Library Stock Alert Service, SIGLE, Amed), references lists of selected papers, hand searching homeopathic journals and conference abstracts, and contacting pharmaceutical companies. TRIALS SELECTION: Trials were selected using an unblinded process by two reviewers. The selection criteria were randomised, controlled trials in which the efficacy of homeopathic treatment was assessed relative to placebo in patients using clinical or surrogate endpoints. Prevention (...) trials or those evaluating only biological effects were excluded. One hundred and eighteen randomised trials were identified and evaluated for inclusion. Sixteen trials, representing 17 comparisons and including a total of 2,617 evaluated patients, fulfilled the inclusion criteria.Data were extracted by two reviewers independently, using a summary form. Disagreements were resolved by a third person.The evidence was synthesised by combining the significance levels (P values) for the primary outcomes

2000 European journal of clinical pharmacology

7495. [Legal and ethical aspects of drug therapy]. (PubMed)

[Legal and ethical aspects of drug therapy]. Legally speaking, the administration of drugs for diagnostic and therapeutic purposes is, in fact, bodily injury which enjoys exemption from punishment only when it is justified and the patient has given his consent. In daily practice the application of relatively low-risk diagnostic drops ought to represent a part of the commission which the patient gives the ophthalmologist in seeking out his practice. The risk involved in diagnostically (...) ignorance to secure knowledge. Members of the legal profession have expressed their misgivings about randomized studies, partially because they are not familiar with the state of our ignorance and the difficulties involved in testing pharmaceuticals.(ABSTRACT TRUNCATED AT 250 WORDS)

1985 Klinische Monatsblatter fur Augenheilkunde

7496. Repeated mild injury causes cumulative damage to hippocampal cells. (PubMed)

represents the first report on the effects of repeated mechanical insults on specific cells of the brain using an in vitro model system. The biochemical pathways of cellular degradation following repeated mild injuries may differ considerably from those that are activated by a single mild insult. Therefore, we hope to use this model in order to investigate secondary pathways of cellular damage after repeated mild traumatic injury, and as a rapid and economical means of screening possibilities (...) for treatment strategies, including pharmaceutical intervention.

2002 Brain

7497. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. (PubMed)

) and TR grade (none to mild 977 +/-28 days, moderate 737 +/-40 days, severe 658 +/-55 days, P =.0001).Patients with severe MR or TR represent high-risk subsets of patients with LVSD. Future study is warranted to determine whether pharmaceutical or surgical strategies to relieve MR and TR have a favorable impact on survival.

2002 American Heart Journal

7498. Barriers and facilitators to enrollment in cancer clinical trials: qualitative study of the perspectives of clinical research associates. (PubMed)

to accrual.Focus groups were held at six of eight tertiary cancer centers in Ontario, Canada. Audiotapes of sessions were transcribed and subjected to content analysis by two of the authors. Emergent themes were identified. These themes are illustrated by representative quotes taken from the transcripts.Factors that acted as barriers or facilitators were classified into physician-related, patient-related, or system-related factors. CRAs identified physician attitudes regarding patient participation (...) as the principal physician-related barrier. Barriers, facilitators, and modifying factors that were related to patient involvement were discussed by CRAs. Patients seemed more knowledgeable about trials than in the past and were willing to participate. System factors were considered to have the greatest impact on the ability to accrue. CRAs identified increasing trial and pharmaceutical demands coupled with tight trial time lines. Time was seen as a diminishing resource. Greater demands not only affect

Full Text available with Trip Pro

2002 Cancer

7499. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK

Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK Lenox-Smith A, Conway P, Knight C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) in the meta-analysis of Einarson et al. (see Other Publications of Interest). The TCA study was considered representative of the class, as the response rate was within the 95% confidence interval (CI) of the Einarson meta-analysis. Methods used to judge relevance and validity, and for extracting data Not reported. Number of primary studies included Two studies were included in the review. One was a meta-analysis of 8 primary studies, while the other was a randomised study. Methods of combining primary

2004 NHS Economic Evaluation Database.

7500. Community pharmacy based provision of pharmaceutical care to older patients

and benefits The costs and benefits were not combined. Authors' conclusions The provision of pharmaceutical care to community dwelling patients resulted in an improvement in medication compliance, a reduction in the number of patient-reported problems and evidence of cost-savings. CRD COMMENTARY - Selection of comparators A justification was given for the comparator used. It represented current practice in the authors' setting. However, the authors did not provide any details of what current practice (...) Community pharmacy based provision of pharmaceutical care to older patients Community pharmacy based provision of pharmaceutical care to older patients Community pharmacy based provision of pharmaceutical care to older patients Sturgess I K, McElnay J C, Hughes C M, Crealey G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

2003 NHS Economic Evaluation Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>